Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBITDA Margin (2017 - 2025)

Organogenesis Holdings (ORGO) has 9 years of EBITDA Margin data on record, last reported at 28.05% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1998.0% year-over-year to 28.05%; the TTM value through Dec 2025 reached 7.92%, up 819.0%, while the annual FY2025 figure was 7.92%, 819.0% up from the prior year.
  • EBITDA Margin reached 28.05% in Q4 2025 per ORGO's latest filing, up from 13.74% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 28.05% in Q4 2025 and bottomed at 30.85% in Q1 2025.
  • Average EBITDA Margin over 5 years is 4.43%, with a median of 7.48% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: surged 3674bps in 2021, then plummeted -2735bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 15.45% in 2021, then tumbled by -51bps to 7.55% in 2022, then crashed by -117bps to 1.27% in 2023, then soared by 734bps to 8.07% in 2024, then surged by 248bps to 28.05% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 28.05% in Q4 2025, 13.74% in Q3 2025, and 12.45% in Q2 2025.